CMXCD
StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home … Read more
CMXCD (CMXCD) - Net Assets
Latest net assets as of May 2025: $-1.25 Million USD
Based on the latest financial reports, CMXCD (CMXCD) has net assets worth $-1.25 Million USD as of May 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.22K) and total liabilities ($1.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.25 Million |
| % of Total Assets | -5872.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CMXCD - Net Assets Trend (2021–2025)
This chart illustrates how CMXCD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CMXCD (2021–2025)
The table below shows the annual net assets of CMXCD from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-05-31 | $-1.25 Million | -50.80% |
| 2024-05-31 | $-826.46K | +65.35% |
| 2023-05-31 | $-2.39 Million | -18.74% |
| 2022-05-31 | $-2.01 Million | -27.47% |
| 2021-05-31 | $-1.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CMXCD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 190120000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $9.62 Million | % |
| Total Equity | $-1.25 Million | 100.00% |
CMXCD Competitors by Market Cap
The table below lists competitors of CMXCD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EKF DIAGNOSTICS
BE:LYF
|
$2.48K |
|
creditshelf Aktiengesellschaft
F:CSQ
|
$2.48K |
|
HHGregg Inc. (IN)
PINK:HGGG
|
$2.48K |
|
Alphanam M&E
VN:AME
|
$2.48K |
|
Petro Vietnam LPG JSC
VN:PVG
|
$2.48K |
|
RSID3F
SA:RSID3F
|
$2.48K |
|
Ismailia Misr Poultry
EGX:ISMA
|
$2.48K |
|
MRDIYT
BK:MRDIYT
|
$2.48K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CMXCD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -826,455 to -1,246,286, a change of -419,831.
- Net loss of 566,293 reduced equity.
- Other factors increased equity by 146,462.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-566.29K | -45.44% |
| Other Changes | $146.46K | +11.75% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CMXCD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-05-31 | $-0.38 | $0.26 | x |
| 2022-05-31 | $-0.48 | $0.26 | x |
| 2023-05-31 | $-0.57 | $0.26 | x |
| 2024-05-31 | $-0.04 | $0.26 | x |
| 2025-05-31 | $-0.06 | $0.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CMXCD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -13469.92% | 0.13x | 0.00x | $-753.23K |
| 2022 | 0.00% | -11498.42% | 0.15x | 0.00x | $-496.48K |
| 2023 | 0.00% | -17923.32% | 0.03x | 0.00x | $-256.49K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-59.84K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-441.66K |
Industry Comparison
This section compares CMXCD's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CMXCD (CMXCD) | $-1.25 Million | 0.00% | N/A | $2.48K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |